JP Morgan Chase’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

JP Morgan Chase’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-14	Closed	-$3K	–	5998
2018 Q3	$3K	Buy	+14	New	+$33.6K	﹤0.01%	5593

Other funds holding ONCT

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

JP Morgan Chase's ONCT Position: Q4 2024 in Review

JP Morgan Chase sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 1,111 shares — an estimated $1.47K sold.

JP Morgan Chase first reported a position in ONCT in Q3 2017 and held it in 22 quarters. The position peaked at $171K in Q3 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

JP Morgan Chase reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
JP Morgan Chase sold 1,111 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $1.47K.
JP Morgan Chase first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2017 and held it in 22 quarters.
JP Morgan Chase's Oncternal Therapeutics, Inc. Common Stock position peaked at $171K in Q3 2021.
4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.